Study details
Enrolling now
Convalescent Plasma as a Possible Treatment for COVID-19
University of Illinois at Chicago
NCT IDNCT04442191ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 1 year
Ages
40+
Locations
1 site in IL
What this study is about
Researchers are testing if convalescent plasma, which contains antibodies from people who have recovered from COVID-19, can help people who are currently ill with the virus. The trial will compare this treatment to a placebo (an inactive substance) and assess its safety. It will last for 365 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Convalescent plasma
- 2.Receive Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: C-reactive Protein (CRP)
Body systems
Infectious